Nasdaq:OPRX
OptimizeRx Corp
A direct-to-consumer digital health platform focused on optimizing patient medication adherence through technology-enabled care.
Key Metrics
Investment Thesis
Bull Case
OPRX demonstrates impressive top-line growth with revenue nearly doubling over the last two years, suggesting strong product-market fit and scalable unit economics. The positive operating cash flow indicates that core business operations are generating liquidity despite accounting losses driven by non-cash adjustments and stock-based comp.
Bear Case
The company remains unprofitable with a widening net loss trend from -$11.4M in 2022 to -$20.1M in 2024, which could deter value investors waiting for earnings turnaround. Significant accumulated debt of $30.8M long-term and a deep retained earnings deficit create financial pressure that must be resolved before sustainable growth resumes.
About OptimizeRx Corp
OptimizeRx Corp (OPRX) operates as a direct-to-consumer digital health platform connecting patients with healthcare professionals to optimize prescription adherence. Serving the broader US market through its online portal, the company leverages proprietary technology to deliver personalized care plans and medication management services.
Analysis
Management Discussion
While revenue grew strongly by 30% year-over-year to $92.1M, the company expanded at the expense of profitability, resulting in a net loss of $20.1M and negative operating profit of $13.7M. Cash flow from operations was positive at $4.9M, partially offset by significant share-based compensation of $11.5M and debt repayments of $4.0M.
Industry Overview
The digital therapeutics and direct-to-consumer health market is rapidly expanding as patients seek convenient, technology-enabled solutions for chronic disease management. Regulatory bodies are increasingly scrutinizing reimbursement models for digital health tools, creating both opportunities for innovation and risks for non-compliant players.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $62.5M | $71.5M | $92.1M |
| Cost of Revenue | $23.5M | $28.6M | $32.7M |
| Gross Profit | $39.0M | $42.9M | $59.4M |
| Operating Expenses | $51.3M | $69.3M | $73.1M |
| Operating Income | $-12.3M | $-26.4M | $-13.7M |
| G&A | $33.5M | — | — |
| Stock-Based Comp | $15.7M | $13.7M | $11.5M |
| D&A | $2.0M | $2.4M | $4.3M |
| Depreciation | $85.7K | $99.8K | $111.0K |
| Amortization | — | — | $4.2M |
| Other OpEx | $17.8M | — | — |
| Non-Operating Income | $852.3K | $0 | $-5.7M |
| Interest Expense | — | $1.5M | — |
| Interest Income | — | $2.2M | $329.0K |
| Pre-Tax Income | $-11.4M | $-26.4M | $-19.4M |
| Income Tax | $0 | $-7.6M | $725.0K |
| Continuing Ops | $-11.4M | $-18.8M | $-20.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-11.4M | $-17.6M | $-20.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-11.4M | $-17.6M | $-20.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $98.6M | $54.3M | $54.0M |
| Cash & Equivalents | $18.2M | $13.9M | $13.4M |
| Marketable Securities | $55.9M | — | — |
| Accounts Receivable | $22.2M | $36.3M | $38.2M |
| Prepaid Expenses | — | $3.2M | $2.4M |
| Other Current Assets | $2.3M | $1.0M | $0 |
| Long-Term Assets | $36.1M | $129.0M | $117.2M |
| PP&E (Net) | $137.4K | $149.4K | $150.0K |
| Goodwill | $22.7M | $78.4M | $70.9M |
| Operating Leases | $235.3K | $572.9K | $366.0K |
| Other LT Assets | $13.0M | $50.0M | $45.8M |
| Total Assets | $134.7M | $183.4M | $171.2M |
| Current Liabilities | $8.4M | $17.9M | $18.7M |
| Current Debt | — | $2.0M | $2.0M |
| Current Leases | $89.9K | $221.6K | $168.0K |
| Deferred Revenue | — | — | $473.0K |
| Other Current Liab | $5.7M | $7.9M | $7.5M |
| Long-Term Liabilities | $144.5K | $38.9M | $35.5M |
| Long-Term Debt | — | $34.2M | $30.8M |
| LT Operating Leases | $144.5K | $371.4K | $209.0K |
| Other LT Liab | $0 | $4.3M | $4.5M |
| Total Liabilities | $8.5M | $56.8M | $54.2M |
| Shareholders' Equity | $126.1M | $126.6M | $117.0M |
| Paid-In Capital | $172.8M | $190.8M | $201.3M |
| Retained Earnings | $-46.7M | $-64.3M | $-84.4M |
| Treasury Stock | $1.2K | $1.7K | $2.0K |
| Total L&E | $134.7M | $183.4M | $171.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-11.4M | $-17.6M | $-20.1M |
| Non-Cash Adjustments | $25.0M | $-6.6M | $20.9M |
| Working Capital Changes | $-2.9M | $16.9M | $4.1M |
| Cash from Operations | $10.7M | $-7.2M | $4.9M |
| Capital Expenditures | $81.0K | $87.1K | $112.0K |
| Cash from Investing | $-58.2M | $-25.3M | $-450.0K |
| Debt Repayments | — | $1.7M | $4.0M |
| Share Buybacks | $20.0M | $7.5M | — |
| Cash from Financing | $-19.0M | $28.2M | $-4.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-66.5M | $-4.4M | $-472.0K |
| Beginning Cash | $84.7M | $18.2M | $13.9M |
| Ending Cash | $18.2M | $13.9M | $13.4M |
Frequently Asked Questions
How does OptimizeRx Corp make money?
The company generates revenue primarily through direct patient subscriptions and service fees for managing prescription therapy, supplemented by data analytics services sold to pharmaceutical partners and healthcare providers.
What are the main risks for OPRX?
Persistent net losses of $20.1M in 2024 raising concerns about path to profitability; High cash burn rate coupled with a significant retained earnings deficit of $84.4M; Regulatory changes affecting digital health reimbursement models; Intense competition from established telehealth giants and new entrants.
What is OPRX's competitive advantage?
Proprietary AI-driven algorithms that personalize care plans for better adherence rates; First-mover advantage in the direct-to-consumer digital therapeutics space; Scalable SaaS model with high gross margins relative to traditional healthcare services.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.